Claims
- 1. A method of treating depression in a human which comprises administering to a human in need of antidepressant therapy, an amount of (+)-sibutramine, or a pharmaceutically acceptable salt thereof, substantially free of its (−)-stereoisomer, said amount being sufficient to alleviate depression.
- 2. A method of treating depression in a human according to claim 1 in which said amount of (+)-sibutramine or a pharmaceutically acceptable salt thereof, substantially free of its (−)-stereoisomer, is sufficient to alleviate depression but insufficient to cause adverse effects associated with the administration of racemic sibutramine.
- 3. The method of claims 1 or 2 wherein (+)-sibutramine is administered by intravenous infusion, transdermal delivery, or orally as a tablet or a capsule.
- 4. The method of claim 3 wherein the amount administered is from about 1 mg to about 60 mg per day.
- 5. The method of claim 4 wherein the amount administered is from about 2 mg to about 50 mg per day.
- 6. The method of claim 5 wherein the amount administered is from about 5 mg to about 45 mg per day.
- 7. The method of claim 3 wherein the amount of (+)-sibutramine or a pharmaceutically acceptable salt thereof is greater than approximately 90% by weight of the total amount of sibutramine.
- 8. The method of claim 3 wherein the (+)-sibutramine or a pharmaceutically acceptable salt thereof, substantially free of its (−)-stereoisomer, is administered together with a pharmaceutically acceptable carrier.
- 9. The method according to claim 3 wherein (+)-sibutramine is administered as a hydrochloride salt.
- 10. A method for treating obesity or weight gain in a human which comprises administering to a human in need of a reduction in weight, an amount of (+)-sibutramine or a pharmaceutically acceptable salt thereof, substantially fie of its (−)stereoisomer, said amount being sufficient to alleviate obesity or weight gain.
- 11. A method for treating obesity or weight gain in a human according to claim 10 wherein said amount is sufficient to alleviate obesity or weight gain but insufficient to cause adverse effects associated with administration of racemic sibutramine.
- 12. The method of claims 10 or 11 wherein (+)-sibutramine is administered by intravenous infusion, transdermal delivery, or orally as a tablet or a capsule.
- 13. The method of claim 12 wherein the amount administered is from about 1 mg to about 60 mg per day.
- 14. The method of claim 13 wherein the amount administered is from about 2 mg to about 50 mg per day.
- 15. The method of claim 14 wherein the amount administered is from about 5 mg to about 45 mg per day.
- 16. The method of claim 15 wherein the amount of (+)-sibutramine or a pharmaceutically acceptable salt thereof is greater than approximately 90% by weight of the total amount of sibutramine.
- 17. The method of claim 12 wherein the (+)-sibutramine or a pharmaceutically acceptable salt thereof, substantially free of its (−)-stereoisomer, is administered together with a pharmaceutically acceptable carrier.
- 18. The method according to claims 10 or 11 wherein (+)-sibutramine is administered as a hydrochloride salt.
- 19. A method of treating disorders ameliorated by inhibition of neuronal monoamine reuptake in a human which comprises administering to a human in need of such treatment an amount of (+)-sibutramine or a pharmaceutically acceptable salt thereof, substantially free of its (−)-stereoisomer, said amount being sufficient to alleviate said disorders.
- 20. A method of treating disorders ameliorated by inhibition of neuronal monoamine reuptake in a human according to claim 19 in which said amount is sufficcient to alleviate said disorders but insufficient to cause adverse effects associated with administration of racemic sibutramine.
- 21. A method of treating disorders ameliorated by inhibition of neuronal monoamine reuptake in a human according to claims 19 or 20 wherein said monoamine is dopamine.
- 22. A method of treating disorders ameliorated by inhibition of neuronal monoamine reuptake in a human according to claims 19 or 20 wherein said disorder is Parkinson's disease.
- 23. The method of claims 19 or 20 wherein (+)-sibutramine is administered by intravenous infusion, transdermal delivery, or orally as a tablet or a capsule.
- 24. The method of claim 23 wherein the amount administered is from about 1 mg to about 60 mg per day.
- 25. The method of claim 24 wherein the amount administered is from about 2 mg to about 50 mg per day.
- 26. The method of claim 25 wherein the amount administered is from about 5 mg to about 45 mg per day.
- 27. The method of claim 23 wherein the amount of (+)-sibutramine or a pharmaceutically acceptable salt thereof is greater than approximately 90% by weight of the total amount of sibutramine.
- 28. The method of claim 23 wherein (+)-sibutramine or a pharmaceutically acceptable salt thereof, substantially free of its (−)-stereoisomer is administered together with a pharmaceutically acceptable carrier.
- 29. The method according to claim 23 wherein (+)-sibutramine is administered as a hydrochloride salt.
RELATED APPLICATIONS
This application claims priority to U.S. Provisional Application Serial No. 60/125,320, entitled “Therapeutic Agent,” filed on Mar. 19, 1999; the entire contents of which are hereby incorporated herein by reference.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
4522828 |
Jeffery et al. |
Jun 1985 |
A |
4939175 |
Ukai et al. |
Jul 1990 |
A |
5436272 |
Scheinbaum |
Jul 1995 |
A |
6323242 |
Mueller |
Nov 2001 |
B1 |
Foreign Referenced Citations (8)
Number |
Date |
Country |
230742 |
Sep 1990 |
EP |
282206 |
Nov 1990 |
EP |
397831 |
Sep 1993 |
EP |
2098602 |
Nov 1982 |
GB |
WO 9520949 |
Aug 1995 |
WO |
WO 9811884 |
Mar 1998 |
WO |
WO 9813033 |
Apr 1998 |
WO |
WO 9813034 |
Apr 1998 |
WO |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/125320 |
Mar 1999 |
US |